Minerva

The wonders of statins and other stories . . .

BMJ 2013; 347 doi: https://doi.org/10.1136/bmj.f6979 (Published 27 November 2013) Cite this as: BMJ 2013;347:f6979

Minerva thinks that statins are wonderful drugs. Not only have they saved the lives of millions of people at increased risk of cardiovascular disease, but they may also reduce all cause and cancer specific mortality in men with prostate cancer. A study of four large UK databases in the Journal of Clinical Oncology (2013, doi:10.1200/JCO.2013.49.4757) found that men who were taking statins at the time of diagnosis had a 34% reduction in adjusted all cause mortality after a mean follow-up of 4.4 years. Men who started statins after the diagnosis of prostate cancer had a smaller but still significant 18% reduction in all cause mortality, with a cumulative dose related effect. Observed reductions in prostate cancer related mortality in both statin groups were even larger, pointing to a cancer specific effect.

Statins also reduce recurrent venous thromboembolism, according to a prospective cohort study of all patients with a hospital diagnosis of venous thromboembolism in Denmark during 1997-2009 who received a prescription for warfarin …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe